Chlorproguanil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Chlorproguanil
DrugBank Accession Number
DB12314
Background

Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 288.18
Monoisotopic: 287.0704509
Chemical Formula
C11H15Cl2N5
Synonyms
  • Chlorproguanil
  • Chlorproguanilum
  • Clorproguanil

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Artemether.
ButaperazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Butaperazine.
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Chlorpromazine.
DapsoneThe risk or severity of adverse effects can be increased when Chlorproguanil is combined with Dapsone.
FluphenazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Fluphenazine.
LumefantrineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Lumefantrine.
MefloquineMefloquine may increase the QTc-prolonging activities of Chlorproguanil.
MesoridazineThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Mesoridazine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Chlorproguanil hydrochloride6T04V14CU96001-93-0SVJMILFDDBKCGG-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Biguanides / Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organochlorides / Imines / Hydrocarbon derivatives
Substituents
1,2-dichlorobenzene / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Biguanide / Carboximidamide / Guanidine / Hydrocarbon derivative / Imine / Organic 1,3-dipolar compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
8O3249M729
CAS number
537-21-3
InChI Key
ISZNZKHCRKXXAU-UHFFFAOYSA-N
InChI
InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
IUPAC Name
1-[N'-(3,4-dichlorophenyl)carbamimidamido]-N-(propan-2-yl)methanimidamide
SMILES
CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1

References

General References
Not Available
PubChem Compound
9571037
PubChem Substance
347828579
ChemSpider
20950
ChEBI
135192
ChEMBL
CHEMBL1213553
ZINC
ZINC000000001136
PharmGKB
PA165857067
Wikipedia
Chlorproguanil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentMalaria caused by Plasmodium falciparum2
3CompletedNot AvailableMalaria caused by plasmodium vivax / Plasmodium Infections1
3CompletedTreatmentFever / Plasmodium Infections1
3CompletedTreatmentMalaria caused by Plasmodium falciparum2
3CompletedTreatmentPlasmodium Infections2
3TerminatedTreatmentPlasmodium Infections1
2CompletedTreatmentPlasmodium Infections1
2, 3CompletedDiagnosticPlasmodium Infections1
1SuspendedTreatmentPlasmodium Infections1
Not AvailableCompletedPreventionAnemia / Plasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0808 mg/mLALOGPS
logP2.88ALOGPS
logP2.99ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)10ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area83.79 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.46 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 21:55 / Updated on February 21, 2021 18:53